On February 13th, Japan Tobacco Inc. (JTI) released its financial report for the year 2024. The report showed that sales revenue for 2024 reached 3.15 trillion Japanese yen (approximately 20.5 billion US dollars), representing a year-on-year increase of 10.9%. Operating profit was 697.2 billion yen (approximately 4.5 billion US dollars), a year-on-year increase of 3.7%, while net profit attributable to the company's owners was 463.4 billion yen (approximately 3 billion US dollars), a year-on-year decrease of 3.9%.
A report shows that Japan Tobacco is gradually expanding its diversified business layout, with tobacco remaining the core revenue driver contributing a revenue of 2.78 trillion yen (approximately $18 billion). The growth mainly comes from the Asian, European, and Middle East/Africa (EMA) markets, indicating that Japan Tobacco continues to maintain competitiveness in the global tobacco market.
The sales of the pharmaceutical business slightly declined to 94.4 billion yen (approximately 0.62 billion US dollars). The report attributed this decrease primarily to intensified market competition. On the other hand, the food business showed growth momentum, with sales reaching 157.2 billion yen (approximately 1 billion US dollars), contributing to the diversification of the group's revenue.
Japan Tobacco Inc. has forecasted its performance for the year 2025, expecting sales revenue to continue growing by 3.9% to reach 3.27 trillion yen (approximately 21.2 billion US dollars). Adjusted operating profit is projected to decrease by 2.2% to 735 billion yen (about 4.8 billion US dollars). Net profit attributable to owners of the parent company is expected to drop by 2.9% to 450 billion yen (around 3 billion US dollars).
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
